← Patent-cliff monitor small molecule KRAZATI ADAGRASIB
Loss of exclusivity August 2043 latest FDA-listed patent expiry
Company BRISTOL MYERS SQUIBB CO
Drug detail Brand name KRAZATI Active ingredient ADAGRASIB Strength 200MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2022 Marketing status RX
Listed patents Patent Expires Type 12653789 August 2043 product 12383503 August 2043 product 12281113 September 2041 substance, product 12336995 February 2041 use U-3953 10689377 May 2037 substance, product
Regulatory exclusivity Code Expires ODE-352 December 2029 NCE December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.